- Open Access
Acute IL-1RA treatment suppresses the peripheral and central inflammatory response to spinal cord injury
Journal of Neuroinflammation volume 18, Article number: 15 (2021)
The acute phase response (APR) to CNS insults contributes to the overall magnitude and nature of the systemic inflammatory response. Aspects of this response are thought to drive secondary inflammatory pathology at the lesion site, and suppression of the APR can therefore afford some neuroprotection. In this study, we examined the APR in a mouse model of traumatic spinal cord injury (SCI), along with its relationship to neutrophil recruitment during the immediate aftermath of the insult. We specifically investigated the effect of IL-1 receptor antagonist (IL-1RA) administration on the APR and leukocyte recruitment to the injured spinal cord.
Adult female C57BL/6 mice underwent either a 70kD contusive SCI, or sham surgery, and tissue was collected at 2, 6, 12, and 24 hours post-operation. For IL-1RA experiments, SCI mice received two intraperitoneal injections of human IL-1RA (100mg/kg), or saline as control, immediately following, and 5 hours after impact, and animals were sacrificed 6 hours later. Blood, spleen, liver and spinal cord were collected to study markers of central and peripheral inflammation by flow cytometry, immunohistochemistry and qPCR. Results were analysed by two-way ANOVA or student’s t-test, as appropriate.
SCI induced a robust APR, hallmarked by elevated hepatic expression of pro-inflammatory marker genes and a significantly increased neutrophil presence in the blood, liver and spleen of these animals, as early as 2 hours after injury. This peripheral response preceded significant neutrophil infiltration of the spinal cord, which peaked 24 hours post-SCI. Although expression of IL-1RA was also induced in the liver following SCI, its response was delayed compared to IL-1β. Exogenous administration of IL-1RA during this putative therapeutic window was able to suppress the hepatic APR, as evidenced by a reduction in CXCL1 and SAA-2 expression as well as a significant decrease in neutrophil infiltration in both the liver and the injured spinal cord itself.
Our data indicate that peripheral administration of IL-1RA can attenuate the APR which in turn reduces immune cell infiltration at the spinal cord lesion site. We propose IL-1RA treatment as a viable therapeutic strategy to minimise the harmful effects of SCI-induced inflammation.
Systemic inflammatory response syndrome (SIRS) is a major and frequent complication in trauma patients with a spinal cord injury (SCI). Development of SIRS not only has the potential to cause multi-organ damage and/or dysfunction [1, 2], it is also thought to influence inflammatory pathology and lesion site development in the injured central nervous system (CNS) itself, including following brain or spinal cord insult. Previous studies from our lab have demonstrated that the latter is heavily influenced by the magnitude of early systemic inflammatory changes, a process referred to as the acute phase response (APR), which predominantly occurs in the liver [3,4,5,6,7]. Here, pro-inflammatory cytokines and chemokines as well as acute phase proteins (APPs) are upregulated as early as 2 hours post-injury [5, 7,8,9,10]. These mediators contribute to the mobilisation and priming of leukocytes, facilitating their translocation to sites of CNS injury.
Neutrophils are the first peripheral immune cells to be recruited to CNS lesion sites, including in SCI , and they are known to release proteases and generate oxidative species [12, 13]. In peripheral trauma, this enables degradation of debris which is beneficial to the host. However, in the CNS, this causes further membrane damage, lipid peroxidation, DNA fragmentation and cellular injury . Activated neutrophils also release pro-inflammatory mediators, which can contribute to the development of a chronic immune response [15, 16] and exacerbate the neurological deficit .
Interleukin-1β (IL-1β) is a key early component of the APR and cytokine cascade initiated after SCI. Undetectable in the uninjured cord [18, 19], this pro-inflammatory cytokine is significantly upregulated within 1 hour of injury [20,21,22,23], and thought to play a pivotal role in the recruitment of various leukocyte subsets [24,25,26]. Early inhibition of IL-1β signalling could therefore be of significant benefit. IL-1 receptor antagonist (IL-1RA) is an endogenous competitive antagonist that inhibits IL-1 signalling and subsequent downstream pro-inflammatory events . IL1-RA expression in the injured CNS is initially downregulated compared to IL-1β , but its exogenous administration can lead to improvements in cognitive deficits [28, 29], tissue loss  and leukocyte recruitment [30, 31] in models of traumatic brain injury (TBI) and stroke. IL-1RA has also been used in models of SCI [32,33,34] but the focus, as with studies in the brain, has tended to be on its suppressive effects in the CNS only. With recent papers demonstrating important interactions between migrating neutrophils and components of the CNS immune system , a better understanding of the peripheral effects of IL-1RA treatment is highly significant as it potentially negates the need to circumvent the precarious blood-CNS barrier.
In this paper we investigated the peripheral immune response to a lower thoracic SCI and determined how treatment with the endogenous antagonist IL-1RA impacted on the APR and neutrophil recruitment to the injured spinal cord.
Female C57BL/6J mice, 8-12 weeks old, were used in this study, as described previously [36, 37], due to reduced risk of post-operative complications. Animals were obtained from the Animal Resource Centre (Canningvale, Western Australia) and housed in individually ventilated cages in a specific pathogen-free facility, under standard diurnal lighting conditions (12 hours) with ad libitum access to food and water. The experimental holding room had temperature (21.5 °C set point) and humidity control (40% set point), and was supplied with HEPA-filtered air. Animals were allowed to acclimatise for 4 weeks prior to experiments. All experiments were approved by The University of Queensland’s Animal Ethics Committee (Anatomical Biosciences) and were conducted in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes.
Spinal cord injury model
Mice were anaesthetised by intraperitoneal injection using a combination of tiletamine/zolezepam (50mg/kg; Virbac) and xylazine (10mg/kg; Troy Laboratories). Following incision of the skin over the lower thoracic region of the back, the paravertebral muscles were separated and anatomical landmarks utilised to identify T9 . A dorsal laminectomy was then performed to expose the spinal cord [39,40,41], after which the vertebral column was clamped for stabilisation and a moderate contusive 70kDyne (kD) SCI inflicted using the Infinite Horizon Impactor (Precision Systems and Instrumentation). Muscle and skin were then closed with 6-90 polygalactin dissolvable sutures (Ethicon) and Michel wound clips (Kent Scientific), respectively. Age- and weight-matched sham-operated controls were subjected to laminectomy only. All mice received a single dose of buprenorphine in Hartmann’s sodium lactate (1mg/kg; sub cutaneous; Sigma Aldrich) post-surgery. Naïve control mice, which were included for baseline results, did receive anaesthesia but no surgical intervention.
Animals received two intraperitoneal injections of human IL-1RA (100mg/kg), the first immediately following impact whilst still under general anaesthesia, and the second 5 hours post-injury. This treatment regime was based on previous papers reporting neuroprotective effects of IL-1RA in models of CNS injury [30, 42].
Sample collection and processing
For time-course analysis, animals were allowed to survive for 2, 6, 12 and 24 hours post-surgery. For IL-1RA experiments, animals were culled 6 hours post-surgery.
All mice were anaesthetised with 4% isoflurane and blood was collected by cardiac puncture into a heparinised tube (BD Microtainer). Mice were then transcardially perfused with 20mL of heparinised saline (0.9% NaCl, 10IU/mL heparin (Pfizer), 2% NaNO3) and fresh liver and spleen samples collected for qPCR. Liver was snap-frozen in liquid nitrogen and stored at -80°C, whilst spleen was processed immediately for flow cytometry (see below). Mouse cadavers were then transcardially perfused with 30mL of Zamboni’s fixative (2% picric acid, 2% paraformaldehyde, pH 7.2-7.4), and fixed liver and spinal column samples removed and stored in fixative overnight at 4°C. Spinal cords were extracted from the columns the following day and post-fixed at 4°C for an additional 24 hours. Tissues were cryoprotected (overnight incubations in 10% and 30% sucrose solution), embedded in optimal cutting temperature compound (OCT, ProSciTech), then snap-frozen in dry ice-cooled 2-methyl-butane and stored at -80°C until further use. Fixed liver (10μm) and spinal cord (transverse, 20μm) were sectioned using a Leica Cryostat (CM1850).
Fresh spleen samples were mechanically dissociated through a 70μm cell strainer (Life Technologies) and splenocytes pelleted through low-speed centrifugation (300g for 10 minutes). Cells were then resuspended in 5mL of red blood cell (RBC) lysis buffer, incubated for 5 minutes at room temperature (RT), before being centrifuged again and resuspended in Dulbecco’s PBS (DPBS); 5 million splenocytes per sample were used for analysis. Blood samples were diluted 1:5 in RBC lysis buffer for 5 minutes at RT, after which they were centrifuged and resuspended in 100μl of DPBS for analysis.
To exclude dead cells, splenocyte and blood samples were incubated with Zombie Green or Zombie Near Infrared (1:100 in DPBS), respectively, for 20 minutes at RT in the dark. CD16/32 FC block (BD Biosciences), diluted 1:200 in blocking buffer (0.5% Bovine serum albumin [BSA], 2mM EDTA in DPBS), was used to prevent non-specific antibody binding. Samples were immunolabelled for 20 minutes in the dark with Alexa Fluor® 647 rat α-mouse Ly6G (1A8; 1:100; BioLegend), V450 rat α-mouse Ly6C (AL-21; 1:100; BD Horizon), PE rat α-mouse F4/80 (1:50; BD Biosciences) and BV 785TM rat α-mouse/human CD11b (M1/70; 1:100; BioLegend) for spleen, or PE rat α-mouse/human CD11b (M1/70; 1:200; BioLegend) for blood. Next, 1mL of blocking buffer was added and the cells isolated by low-speed centrifugation at 4°C. Cell pellets were resuspended in blocking buffer and then analysed using the LSR II flow cytometer (BD Biosciences) with BD FACS Diva software.
Clumped cells, debris and dead cells were removed during the gating process; neutrophils and monocytes were defined as the CD11b+SSChiLy6G+ and CD11b+SSCloF4/80loLy6G- populations, respectively. Propidium iodide-fluorescing counting beads (10μl; Beckman Coulter) were added to each sample to enable the absolute quantification of cell numbers.
Immunostaining and quantification
For Immunofluorescent staining, fixed spinal cord sections were blocked for non-specific binding with 10% BSA in PBS with 0.3% Triton X-100 for 1 hour at RT. Sections were then incubated overnight at 4°C with primary antibody (rat α-Ly6B.2, 1:200, Bio-Rad). The following day, sections were washed in PBS and incubated in secondary antibody (donkey α-rat 594, 1:400, Jackson Immunoresearch) and Hoechst 33342 nuclear dye (1:1000, Sigma) for 1 hour at RT. Sections were then washed again, mounted with DAKO fluorescent mounting medium (Sigma) and coverslip.
For immunohistochemical staining with the chromogenic reporter 3,3’-Diaminobenzidine (DAB), fixed liver and spinal cord sections were first blocked for endogenous peroxidase activity (1% H2O2 in methanol) and biotin (1:20 in PBS, Vector Labs), followed by incubation with 10% goat serum in PBS for 1 hour at RT to reduce non-specific protein binding. Sections were then incubated overnight at 4°C with primary antibody (rabbit α-MBS neutrophils, 1:10,000, made in house; rabbit α-IBA-1, 1:2000, Abcam), diluted in 1% goat serum in PBS. Next, sections were incubated in goat α-rabbit biotinylated secondary antibody (1:200; Vector Labs) for 2 hours at RT, followed by ABC (1:100; ThermoFisher) for 1 hour at room temperature. After several rounds of washing, sections were incubated in DAB until a satisfactory level of staining was achieved; 1% Harris Haemotoxylin or cresyl violet was used as a counterstain for liver and spinal cord, respectively. Stained sections were dehydrated through graded alcohols (80%, 90%, 2x100%, 5 minutes each), cleared with xylene (2x5 minutes), mounted with non-aqueous mounting medium and coverslipped.
For quantification, stained cells in liver sections were counted directly using a light microscope (Leitz Dialux 20) with an eyepiece grid at x40 magnification, across three sections, in three representative fields per section. For the spinal cord, immunopositive neutrophils were counted at the lesion epicentre and for ±1.0mm in rostral and caudal direction using the either Nikon Eclipse upright automated stereology and slide scanning microscope with Stereo Investigator software (immunofluorescent staining), or the Leitz Dialux 20 light microscope (immunohistochemical staining). All cell counting was performed blinded.
RNA extraction and qPCR
RNA was extracted from approximately 30mg of snap-frozen fresh liver (Qiagen© RNEasy Mini Kit). RNA concentration was measured using a NanoDrop (ThermoFisher) and 1000ng of sample was converted to cDNA using the Applied Biosystems High Capacity cDNA conversion kit. Real-time qPCR was performed with duplicates for each sample (10-25ng/well) using SYBR green qPCR master mix (Applied Biosystems or PrimerDesign) and the Applied Biosystems QuantStudio Flex 7 or Roche LightCycler 480. The following primers were purchased from PrimerDesign: GAPDH (F: AACGACCCCTTCATTGAC, R: TCCACGACATACTCAGCAC), RPL13a (F: GAGGTCGGGTGGAAGTACCA, R: TGCATCTTGGCCTTTTCCTT), IL-1β (F: CAACCAACAAGTGATATTCTCCAT, R: GGGTGTGCCGTCTTTCATTA), CXCL1 (F: GCTGGGATTCACCTCAAGAAC, R: TGTGGCTATGACTTCGGTTTG), CXCL10 (F: CATCCCGAGCCAACCTTCC, R: CACTCAGACCCAGCAGGAT), SAA-2 (F: TGGCTGGAAAGATGGAGACAA, R: AAAGCTCTCTCTTGCATCACTG) and IL-1Rn (F: GACCTTTTACCTGAGAAACAAC, R: TAGGCACCATGTCTATCTTTTC). Relative expression was determined by the 2-ΔΔCt method and normalisation to housekeeping genes (GAPDH and RPL13a).
All analysis was completed with GraphPad Prism 7 software. Unpaired student’s t-test, one- and two-way analysis of variance (ANOVA) were employed, with post-hoc testing as appropriate. Results were considered significant at p<0.05 with 95% confidence intervals. All quantitative data are expressed as mean ± standard error of the mean (SEM).
Surgery induces a robust but differential APR in the liver of sham and SCI mice
We first evaluated the temporal profile of the APR in response to a moderate T9 SCI. Previous work from our group has demonstrated that the level of expression of the mRNA for acute phase proteins is a reliable measure of the acute phase response by the liver, and that the levels reflect the subsequent protein expression levels [5, 9]. The relative expression of IL-1β mRNA (Fig. 1a) and CXCL10 mRNA (Fig. 1b) was elevated in both the sham and SCI groups at 2 hours post-injury. By 6 hours, the expression of these mRNA species had returned to naïve baseline levels in the sham controls, but they remained increased in the SCI mice (IL-1β p<0.01, CXCL10 p<0.05; student’s t-test). Expression of CXCL1 was increased in all operated mice (Fig. 1c), yet it was significantly decreased in the SCI mice compared to the sham controls at both 6 (p<0.05) and 24 hours (p<0.01) post-injury. Expression of SAA-2 (Fig. 1d) was also significantly increased over naïve baseline levels in both sham and SCI mice, although there was a trending decrease in the SCI animals at 6 hours post-injury; direct comparison at this time point indeed revealed a significant difference (p<0.01), which was lost when correcting for multiple comparisons (p=0.182). Lastly, hepatic expression of IL-1RA, the endogenous antagonist to IL-1, was also significantly increased in response to SCI (6 hours post-injury, p<0.05; Fig. 1e), however, peak expression was delayed compared to that of IL-1β expression. Thus, there was a selective increase in the injury-induced expression of specific APR elements (i.e. IL-1β and CXCL10) following SCI while others (CXCL1 and SAA-2) appeared to be suppressed compared to the sham-operated controls. Taken together with the IL-1RA results, these findings highlight the pro- and anti-inflammatory aspects of the SIRS response.
The APR of SCI mice is associated with an increased presence of myeloid cells in the liver that precedes the timing of their recruitment to the spinal cord
We next employed both flow cytometry and immunohistochemistry to investigate downstream myeloid cell responses in the blood, spleen and liver. Circulating CD11b+SSChiLy6G+ granulocytes, representing predominantly neutrophils and a small proportion of basophils and eosinophils, were significantly elevated over naïve baseline in both sham and SCI mice at 2, 6, and 12 hours post-surgery (Fig. 2a). CD11b+SSChiLy6G+ granulocytes were also increased acutely (2-12 hours) in the spleens of all operated mice (Fig. 2b), with trending increases in SCI mice at both 2 (p=0.104) and 6 (p=0.072) hours post-surgery. CD11b+Ly6G- monocytes in the blood were increased in all animals above naïve at 2 hours post-surgery (Fig. 2c). At 6 hours, circulating monocytes in sham animals returned to baseline, but they remained elevated in SCI animals, although this was not statistically significant. In the spleen, the number of CD11b+SSCloF4/80loLy6Clo monocytes showed a non-significant increase at 2 hours, and they then decreased at 6-24 hours in all animals compared to naïve controls (Fig. 2d). Acute increases in (MBS+) neutrophil numbers were also observed in the livers of both sham and SCI mice, although a greater cell density was observed in animals with neurological injury (p<0.05 at 2 and 6 hours, and p=0.055 at 12 hours; Fig. 2e), before returning to baseline control levels by 24 hours post-surgery. The number of Iba-1+ monocytes/macrophages was also elevated in the livers of SCI, but not of sham mice, and they progressively increased over the first 24 hours post-surgery (p<0.05 at 12 hours, p<0.01 at 24 hours; Fig. 2f). Finally, while the liver neutrophil response to SCI (or sham surgery) did mostly subside by 24 hours post-surgery, recruitment/presence of these cells at the spinal cord lesion site continued to increase dramatically over the same time period (p<0.0001; Fig. 3).
Acute treatment with exogenous IL-1RA attenuates the liver APR and reduces neutrophil recruitment to the injured spinal cord
Given the time delay between IL-1β and the reciprocal IL-1RA expression, we investigated the effect of supplementing IL-1RA on inhibiting the IL-1β-mediated peripheral inflammatory response. For this, human IL-1RA (100mg/kg) was administered intraperitoneally immediately after contusive SCI and then again 5 hours later. IL-1RA treatment induced an increase in hepatic IL-1β expression (p<0.01; Fig. 4a) while CXCL10 expression was unchanged (p=0.126; Fig. 4b). However, significant decreases in the expression of CXCL1 (p<0.05; Fig. 4c) and SAA-2 (p<0.01; Fig. 4d) were observed. Consistent with this attenuated APR, the infiltration of neutrophils into the liver was also significantly decreased in IL-1RA-treated SCI mice (p<0.05; Fig. 4e). We lastly evaluated the effect of IL-1RA treatment on central inflammation, i.e. at the spinal cord lesion site itself (Fig. 5). Strikingly, the SCI-induced recruitment of neutrophils here was significantly attenuated by IL-1RA treatment (p<0.001; Fig. 5a). Intraparenchymal IgG staining was not different between groups (Fig. 5b), demonstrating that injury severity was comparable between groups and also that neutrophil recruitment to the lesion site is an active process.
We have consistently demonstrated that insults to the CNS induce a systemic response, known as the APR, that both precedes and amplifies local inflammation at the lesion site [5, 9]. In this study, we investigated the initiation and progression of the APR during the acute phase of SCI (≤24 hours), and whether this could be therapeutically targeted with peripherally administered IL-1RA. We show, to our knowledge for the first time, that systemic IL-1RA treatment indeed suppresses peripheral inflammation in response to SCI, and that this is in turn associated with reduced neutrophil recruitment to the lesion site.
Our previous work showed that CNS insults lead to the rapid induction of pro-inflammatory cytokines, chemokines and acute phase proteins in the liver as early as 2 hours post-injury [5, 7,8,9,10]. These immune mediators are thought to trigger and/or augment the mobilisation and priming of leukocytes in reservoirs such as the bone marrow [1, 36], after which they translocate to both peripheral organs and the site of CNS injury . The present study demonstrates that a robust APR also occurs in mice with a lower thoracic (T9) contusive SCI, with acute increases in hepatic expression of a range of pro-inflammatory genes and an increase in the circulating leukocyte count, particularly neutrophils.
Temporal profiling of the APR demonstrated a significant disconnect between the hepatic expression of IL-1β and IL-1RA in response to SCI, with IL-1β peaking at 2 hours, but IL-1RA not until 6 hours post-injury. Liu et al.  observed a similar dissociation between IL-1β and IL-1RA expression in the injured spinal cord itself, with IL-1β being elevated at 6 hours post-SCI, whilst IL-1RA protein was decreased; a significant increase in IL-1RA protein was observed at 24 hours post-SCI. This delay in IL-1RA expression suggests the existence of putative therapeutic window during which suppression of excessive IL-1β signalling in both the liver and/or spinal cord might be beneficial. Indeed, IL-1β is known to plays a detrimental role in the progression of CNS injury , and IL-1 knock out (KO) mice show improved locomotor activity, reduced lesion volumes and cell survival after SCI [20, 44]. Further data by Boato and colleagues  demonstrated that direct application of IL-1β to the spinal cord lesion site worsened neurological outcome. Moreover, injection of IL-1β into the spinal cord induced neutrophil recruitment . Acute targeting of IL-1 signalling is thus likely to be a viable strategy to reduce secondary damage after SCI [22, 26].
IL-1RA treatment to dampen IL-1 signalling has previously proven neuroprotective in animal models of both stroke [31, 42, 46, 47] and TBI [28,29,30], leading to its progression into human clinical trials for these acquired CNS injuries [48,49,50]. In comparison to brain injuries, treatment of SCI with IL-1RA has been significantly under investigated. Several studies have applied IL-1RA locally to the lesion site itself and reported histological and motor function improvements [27, 32, 51, 52], however, none investigated the influence of this intervention on the APR. Similarly, despite administrating IL-1RA systemically, the studies by Li et al.  and Hasturk et al.  both focused on neurological endpoint markers such as spinal cord lesion size, cell death and/or apoptosis. Our study is therefore the first to explore the role of IL-1 signalling in the hepatic APR and how peripheral administration of IL-1RA affects both the systemic and central inflammatory response to SCI. Perhaps somewhat counterintuitively at first sight, IL-1β expression in the liver was increased after IL-1RA of SCI mice, but this is likely a compensatory response to its blockade. In another acute CNS injury study, it has been shown that the peripheral neutralisation of TNF after stroke gives rise to an increase in hepatic TNF expression, yet the number of granulocytes in the infarct was reduced . Although the underlying mechanisms driving the increase in IL-1β expression following IL-1RA administration are unknown, the critical aspect is that the downstream IL-1-mediated signalling itself is suppressed. Hepatic CXCL1 and SAA-2 expression, which are induced by IL-1β , were indeed decreased, as was neutrophil infiltration into the livers of SCI mice with IL-1RA treatment, which has also been shown to be IL-1β-dependent . Inhibition of IL-1β with IL-1RA during the hyperacute phase after injury thus significantly abrogates the overall hepatic APR.
Exogenous IL-1RA also significantly reduced early neutrophil infiltration to the injured spinal cord. Given the known links between the magnitude of the APR, associated leukocyte mobilisation, and outcome from CNS insults [3, 9, 55], it is tempting to speculate that this reduction in neutrophil recruitment with systemic IL-1RA treatment is due, at least in part, to the observed suppression of the APR. Targeting peripheral inflammation has indeed been demonstrated to be a promising strategy in other CNS injuries, where depletion of liver Kupffer cells  and the targeting of acute phase proteins  reduced both neutrophil infiltration and lesion size. Conversely, systemic IL-1β administration was shown to worsen neutrophilia and increase infiltration of these cells into the brain in a rodent model of stroke . Interestingly, systemic IL-1β administration no longer had a detrimental effect on lesion pathology if neutrophils were depleted . This demonstrates that IL-1β-mediated neutrophil activation and recruitment is the driving factor for excessive CNS damage after injury, and supports the notion that peripheral effects of IL-1RA convey neuroprotection via suppression of this recruitment. These findings have translational significance as the magnitude of neutrophilia is predictive of outcomes in both mice and human patients , and attenuating neutrophil recruitment to the injured spinal cord leads to improved recovery . Targeting the APR thus provides an appealing strategy to reduce the systemic inflammatory response to SCI and, in doing so, ameliorate the spread of secondary injury into spared neural tissue around the impact site. Whilst only female mice have been used in this study, owing to the reduced risk of post-surgery complications, the population of those living with SCI is very heterogeneous. Further studies are therefore warranted to include animals of both sexes and of different ages, to determine whether these factors might affect the response to the IL-1RA treatment.
It must be acknowledged that exogenous IL-1RA may have had some direct effect on the spinal cord itself. Previous studies investigating the pharmacokinetics of IL-1RA report its ability to cross the blood-CNS barrier [58, 59], although uptake of IL-1RA by the CNS is normally extremely poor at around only 1-2% of the plasma concentration . That said, breakdown of the blood-spinal cord barrier after SCI may allow for its passive accumulation here. Pradillo et al.  showed that delayed IL-1RA treatment after stroke reduced infarct volume and also neutrophil infiltration, which was attributed to IL-1RA inhibiting cytokine expression in microglia. The reduction in neutrophil accumulation in the injured spinal cord, as observed in this study, could therefore also be due to direct local suppression of IL-1β signalling at the lesion site. However, the temporal kinetics of the APR and neutrophil mobilisation response to SCI, which precedes the recruitment of these cells to the lesion site and also the peak of IL-1β expression here , strongly suggest that a significant aspect of the therapeutic efficacy of IL-1RA treatment that we observed here was mediated through targeting the peripheral inflammatory response.
In summary, we show that peripheral administration of IL-1RA following SCI attenuates the APR and reduces neutrophil recruitment to the lesion site. Whether this effect is exerted directly or indirectly by suppression of the APR remains the focus of our ongoing research. Considering that IL-1RA treatment is already in clinical trials for other types of acquired CNS injury, our results warrant longer term studies to further explore its use as a viable and translatable treatment for traumatic SCI patients.
Analysis of variance
Acute phase response
Acute phase proteins
Bovine serum albumin
Central nervous system
IL-1 receptor antagonist
Optimal cutting temperature compound
Red blood cell
(Dulbecco’s) phosphate buffered saline
Spinal cord injury
Standard error of the mean
Systemic inflammatory response syndrome
Traumatic brain injury
Bao F, Bailey CS, Gurr KR, Bailey SI, Rosas-Arellano MP, Dekaban GA, et al. Increased oxidative activity in human blood neutrophils and monocytes after spinal cord injury. Exp Neurol. 2009;215:308–16.
Kesani AK, Urquhart JC, Bedard N, Leelapattana P, Siddiqi F, Gurr KR, et al. Systemic inflammatory response syndrome in patients with spinal cord injury: does its presence at admission affect patient outcomes? Clinical article. J Neurosurg Spine. 2014;21:296–302.
Campbell SJ, Anthony DC, Oakley F, Carlsen H, Elsharkawy AM, Blomhoff R, et al. Hepatic nuclear factor kappa B regulates neutrophil recruitment to the injured brain. J Neuropathol Exp Neurol. 2008;67:223–30.
Campbell SJ, Deacon RM, Jiang Y, Ferrari C, Pitossi FJ, Anthony DC. Overexpression of IL-1beta by adenoviral-mediated gene transfer in the rat brain causes a prolonged hepatic chemokine response, axonal injury and the suppression of spontaneous behaviour. Neurobiol Dis. 2007;27:151–63.
Campbell SJ, Perry VH, Pitossi FJ, Butchart AG, Chertoff M, Waters S, et al. Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver. Am J Pathol. 2005;166:1487–97.
Campbell SJ, Wilcockson DC, Butchart AG, Perry VH, Anthony DC. Altered chemokine expression in the spinal cord and brain contributes to differential interleukin-1beta-induced neutrophil recruitment. J Neurochem. 2002;83:432–41.
Wilcockson DC, Campbell SJ, Anthony DC, Perry VH. The systemic and local acute phase response following acute brain injury. J Cereb Blood Flow Metab. 2002;22:318–26.
Blond D, Campbell SJ, Butchart AG, Perry VH, Anthony DC. Differential induction of interleukin-1beta and tumour necrosis factor-alpha may account for specific patterns of leukocyte recruitment in the brain. Brain Res. 2002;958:89–99.
Campbell SJ, Hughes PM, Iredale JP, Wilcockson DC, Waters S, Docagne F, et al. CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury. FASEB J. 2003;17:1168–70.
Campbell SJ, Jiang Y, Davis AE, Farrands R, Holbrook J, Leppert D, et al. Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute-phase response. J Neurochem. 2007;103:2245–55.
Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, et al. The cellular inflammatory response in human spinal cords after injury. Brain. 2006;129:3249–69.
Anwar MA, Al Shehabi TS, Eid AH. Inflammogenesis of secondary spinal cord injury. Front Cell Neurosci. 2016;10:98.
Neirinckx V, Coste C, Franzen R, Gothot A, Rogister B, Wislet S. Neutrophil contribution to spinal cord injury and repair. J Neuroinflammation. 2014;11:150.
Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol. 2008;209:378–88.
Yang L, Jones NR, Blumbergs PC, Van Den Heuvel C, Moore EJ, Manavis J, et al. Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. J Clin Neurosci. 2005;12:276–84.
Zhu L, Liu X, Nemeth DP, DiSabato DJ, Witcher KG, McKim DB, et al. Interleukin-1 causes CNS inflammatory cytokine expression via endothelia-microglia bi-cellular signaling. Brain Behav Immun. 2019;81:292–304.
Morganti-Kossmann C, Raghupathi R, Maas AIR. Traumatic brain and spinal cord injury : challenges and developments. Cambridge: Cambridge University Press; 2012.
Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5:629–40.
Vitkovic L, Bockaert J, Jacque C. "inflammatory" cytokines: neuromodulators in normal brain? J Neurochem. 2000;74:457–71.
Sato A, Ohtaki H, Tsumuraya T, Song D, Ohara K, Asano M, et al. Interleukin-1 participates in the classical and alternative activation of microglia/macrophages after spinal cord injury. J Neuroinflammation. 2012;9:65.
de Rivero Vaccari JP, Lotocki G, Marcillo AE, Dietrich WD, Keane RW. A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci. 2008;28:3404–14.
Pineau I, Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J Comp Neurol. 2007;500:267–85.
Wang CX, Olschowka JA, Wrathall JR. Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res. 1997;759:190–6.
Ching S, He L, Lai W, Quan N. IL-1 type I receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system. Brain Behav Immun. 2005;19:127–37.
Schnell L, Fearn S, Schwab ME, Perry VH, Anthony DC. Cytokine-induced acute inflammation in the brain and spinal cord. J Neuropathol Exp Neurol. 1999;58:245–54.
Pineau I, Sun L, Bastien D, Lacroix S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain Behav Immun. 2010;24:540–53.
Liu S, Xu GY, Johnson KM, Echetebu C, Ye ZS, Hulsebosch CE, et al. Regulation of interleukin-1beta by the interleukin-1 receptor antagonist in the glutamate-injured spinal cord: endogenous neuroprotection. Brain Res. 2008;1231:63–74.
Newell EA, Todd BP, Mahoney J, Pieper AA, Ferguson PJ, Bassuk AG. Combined blockade of interleukin-1alpha and -1beta signaling protects mice from cognitive dysfunction after traumatic brain injury. eNeuro. 2018;5.
Clausen F, Hanell A, Israelsson C, Hedin J, Ebendal T, Mir AK, et al. Neutralization of interleukin-1beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice. Eur J Neurosci. 2011;34:110–23.
Sun M, Brady RD, Wright DK, Kim HA, Zhang SR, Sobey CG, et al. Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma. Brain Behav Immun. 2017;66:359–71.
Pradillo JM, Denes A, Greenhalgh AD, Boutin H, Drake C, McColl BW, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab. 2012;32:1810–9.
Akuzawa S, Kazui T, Shi E, Yamashita K, Bashar AH, Terada H. Interleukin-1 receptor antagonist attenuates the severity of spinal cord ischemic injury in rabbits. J Vasc Surg. 2008;48:694–700.
Li T, Li YT, Song DY. The expression of IL-1beta can deteriorate the prognosis of nervous system after spinal cord injury. Int J Neurosci. 2018;128:778–82.
Hasturk AE, Yilmaz ER, Turkoglu E, Arikan M, Togral G, Hayirli N, et al. Potential neuroprotective effect of Anakinra in spinal cord injury in an in vivo experimental animal model. Neurosciences (Riyadh). 2015;20:124–30.
Otxoa-de-Amezaga A, Miro-Mur F, Pedragosa J, Gallizioli M, Justicia C, Gaja-Capdevila N, et al. Microglial cell loss after ischemic stroke favors brain neutrophil accumulation. Acta Neuropathol. 2019;137:321–41.
Brennan FH, Jogia T, Gillespie ER, Blomster LV, Li XX, Nowlan B, et al. Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. JCI Insight. 2019;4.
Brennan FH, Kurniawan ND, Vukovic J, Bartlett PF, Kasermann F, Arumugam TV, et al. IVIg attenuates complement and improves spinal cord injury outcomes in mice. Ann Clin Transl Neurol. 2016;3:495–511.
Harrison M, O'Brien A, Adams L, Cowin G, Ruitenberg MJ, Sengul G, et al. Vertebral landmarks for the identification of spinal cord segments in the mouse. Neuroimage. 2013;68:22–9.
Blomster LV, Brennan FH, Lao HW, Harle DW, Harvey AR, Ruitenberg MJ. Mobilisation of the splenic monocyte reservoir and peripheral CX(3)CR1 deficiency adversely affects recovery from spinal cord injury. Exp Neurol. 2013;247:226–40.
Blomster LV, Cowin GJ, Kurniawan ND, Ruitenberg MJ. Detection of endogenous iron deposits in the injured mouse spinal cord through high-resolution ex vivo and in vivo MRI. NMR Biomed. 2013;26:141–50.
Scheff SW, Rabchevsky AG, Fugaccia I, Main JA, Lumpp JE Jr. Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J Neurotrauma. 2003;20:179–93.
Pradillo JM, Murray KN, Coutts GA, Moraga A, Oroz-Gonjar F, Boutin H, et al. Reparative effects of interleukin-1 receptor antagonist in young and aged/co-morbid rodents after cerebral ischemia. Brain Behav Immun. 2017;61:117–26.
Gris D, Hamilton EF, Weaver LC. The systemic inflammatory response after spinal cord injury damages lungs and kidneys. Exp Neurol. 2008;211:259–70.
Bastien D, Bellver Landete V, Lessard M, Vallieres N, Champagne M, Takashima A, et al. IL-1alpha gene deletion protects oligodendrocytes after spinal cord injury through upregulation of the survival factor Tox3. J Neurosci. 2015;35:10715–30.
Boato F, Rosenberger K, Nelissen S, Geboes L, Peters EM, Nitsch R, et al. Absence of IL-1beta positively affects neurological outcome, lesion development and axonal plasticity after spinal cord injury. J Neuroinflammation. 2013;10:6.
Maysami S, Wong R, Pradillo JM, Denes A, Dhungana H, Malm T, et al. A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. J Cereb Blood Flow Metab. 2016;36:596–605.
Zhang DD, Jin C, Zhang YT, Gan XD, Zou MJ, Wang YY, et al. A novel IL-1RA-PEP fusion protein alleviates blood-brain barrier disruption after ischemia-reperfusion in male rats. J Neuroinflammation. 2018;15:16.
Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76:1366–72.
Helmy A, Guilfoyle MR, Carpenter KL, Pickard JD, Menon DK, Hutchinson PJ. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow Metab. 2014;34:845–51.
Helmy A, Guilfoyle MR, Carpenter KLH, Pickard JD, Menon DK, Hutchinson PJ. Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury. J Cereb Blood Flow Metab. 2016;36:1434–48.
Nesic O, Xu GY, McAdoo D, High KW, Hulsebosch C, Perez-Pol R. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J Neurotrauma. 2001;18:947–56.
Zong S, Zeng G, Wei B, Xiong C, Zhao Y. Beneficial effect of interleukin-1 receptor antagonist protein on spinal cord injury recovery in the rat. Inflammation. 2012;35:520–6.
Clausen BH, Degn M, Martin NA, Couch Y, Karimi L, Ormhoj M, Mortensen ML, Gredal HB, Gardiner C, Sargent II, et al. Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. J Neuroinflammation. 2014;11:203.
McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci. 2007;27:4403–12.
Fleming JC, Bailey CS, Hundt H, Gurr KR, Bailey SI, Cepinskas G, Lawendy AR, Badhwar A: Remote inflammatory response in liver is dependent on the segmental level of spinal cord injury. J Trauma Acute Care Surg 2012, 72:1194-1201;discussion 1202.
Campbell SJ, Zahid I, Losey P, Law S, Jiang Y, Bilgen M, et al. Liver Kupffer cells control the magnitude of the inflammatory response in the injured brain and spinal cord. Neuropharmacology. 2008;55:780–7.
Lee SM, Rosen S, Weinstein P, van Rooijen N, Noble-Haeusslein LJ. Prevention of both neutrophil and monocyte recruitment promotes recovery after spinal cord injury. J Neurotrauma. 2011;28:1893–907.
Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. 2011;31:439–47.
Greenhalgh AD, Galea J, Denes A, Tyrrell PJ, Rothwell NJ. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol. 2010;160:153–9.
Availability of data and material
All data generated during and/or analysed during the current study are included in this published article.
This work was made possible by a Nathalie Rose Barr Award from the International Spinal Research Trust to AY and the support of SpinalCure Australia to MJR’s laboratory. TJ and ERG are supported by a Research Training Program Scholarship (Australian Government). DA is supported by the UK MRC under grant MC-PC-15029.
Ethics approval and consent to participate
All experiments were approved by The University of Queensland’s Animal Ethics Committee (Anatomical Biosciences) and were conducted in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yates, A.G., Jogia, T., Gillespie, E.R. et al. Acute IL-1RA treatment suppresses the peripheral and central inflammatory response to spinal cord injury. J Neuroinflammation 18, 15 (2021). https://doi.org/10.1186/s12974-020-02050-6
- Systemic inflammatory response syndrome
- Acute phase response
- IL-1 receptor antagonist